Medical genetics firm Invitae (NYSE:NVTA) suffered a shocking fall from grace as insider reports point to an upcoming bankruptcy filing. Although the company forwarded a compelling concept — ...

Invitae (NVTA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

Fintel reports that on May 15, 2023, Raymond James downgraded their outlook for Invitae (NYSE:NVTA) from Market Perform to Underperform. As of May 11, 2023, the average one-year price target for ...

Invitae (NYSE:NVTA) stock popped on investors’ radars earlier this month thanks to its nearly 277% surge in price on Aug 10. Following its latest earnings report, retail traders jumped into the stock ...